Inhibition of spore germination, growth, and toxin activity of clinically relevant C. difficile strains by gut microbiota derived secondary bile acids

Anaerobe

Volumn 45, Issue , 2017, Pages 86-100

  Thanissery, Rajani ^a   Winston, Jenessa A ^a   Theriot, Casey M ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Bile acids; C. difficile; Germination; Growth; Gut microbiota; Metabolome; Toxin

Indexed keywords

BILE ACID; DEOXYCHOLIC ACID; HYODEOXYCHOLIC ACID; ISODEOXYCHOLIC ACID; ISOLITHOCHOLATE; LITHOCHOLIC ACID; OMEGA MURICHOLATE; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; ANTIINFECTIVE AGENT; BACTERIAL TOXIN;

AGE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; GASTROINTESTINAL TRACT; GROWTH INHIBITION; GROWTH RATE; HUMAN; INTESTINE FLORA; LARGE INTESTINE; LIFE CYCLE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SPORE GERMINATION; STRAIN DIFFERENCE; TOXIN ANALYSIS; ANIMAL; ANTIBIOSIS; BACTERIAL SPORE; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIOLOGY; MOUSE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOSIS; BACTERIAL TOXINS; BILE ACIDS AND SALTS; CLOSTRIDIUM DIFFICILE; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; MICE; SPORES, BACTERIAL;

EID: 85015286846     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2017.03.004     Document Type: Article

References (45)

1. Cooper, C.C., Jump, R.L.P., Chopra, T., Prevention of infection due to Clostridium difficile. Infect. Dis. Clin. N. Am. 30:4 (2016 Dec), 999–1012.
2. Lessa, F.C., Mu, Y., Bamberg, W.M., Beldavs, Z.G., Dumyati, G.K., Dunn, J.R., et al. Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 372 (2015), 825–834.
3. C.D.C. Control, Prevention. Antibiotic Resistance Threats in the United States, 2013, 2013, Centres for Disease Control and Prevention, US Department of Health and Human Services.
4. Lucado, J., Gould, C., Elixhauser, A., Clostridium Difficile Infections (CDI) in Hospital Stays, 2009. 2012.
5. Leffler, D.A., Lamont, J.T., Clostridium difficile infection. N. Engl. J. Med. 372 (2015), 1539–1548.
6. Rupnik, M., Wilcox, M.H., Gerding, D.N., Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7 (2009), 526–536.
7. McDonald, L.C., Killgore, G.E., Thompson, A., Owens, R.C. Jr., Kazakova, S.V., Sambol, S.P., et al. An epidemic, toxin gene–variant strain of Clostridium difficile. N. Engl. J. Med. 353 (2005), 2433–2441.
8. C.f.D. Control, prevention. Severe Clostridium difficile-associated disease in populations previously at low risk–four states, 2005. MMWR Morb. Mortal. Wkly. Rep., 54, 2005, 1201.
9. Reeves, A.E., Theriot, C.M., Bergin, I.L., Huffnagle, G.B., Schloss, P.D., Young, V.B., The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes 2 (2011), 145–158.
10. Buffie, C.G., Jarchum, I., Equinda, M., Lipuma, L., Gobourne, A., Viale, A., et al. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect. Immun. 80 (2012), 62–73.
11. Theriot, C.M., Bowman, A.A., Young, V.B., Antibiotic-induced alterations of the gut microbiota alter secondary bile acid production and allow for Clostridium difficile spore germination and outgrowth in the large intestine. mSphere 1:1 (2016), e00045–e00115, 10.1128/mSphere.00045-15.
12. Sayin, S.I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17 (2013), 225–235.
13. Ridlon, J.M., Kang, D.-J., Hylemon, P.B., Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47 (2006), 241–259.
14. Chiang, J.Y., Bile acids: regulation of synthesis. J. Lipid Res. 50 (2009), 1955–1966.
15. Russell, D.W., The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72 (2003), 137–174.
16. Hamilton, J.P., Xie, G., Raufman, J.-P., Hogan, S., Griffin, T.L., Packard, C.A., et al. Human cecal bile acids: concentration and spectrum. Am. J. Physiol. Gastrointest. Liver Physiol. 293 (2007), G256–G263.
17. Setchell, K., Lawson, A., Tanida, N., Sjövall, J., General methods for the analysis of metabolic profiles of bile acids and related compounds in feces. J. Lipid Res. 24 (1983), 1085–1100.
18. Devlin, A.S., Fischbach, M.A., A biosynthetic pathway for a prominent class of microbiota-derived bile acids. Nat. Chem. Biol., 2015, 285–290.
19. Takahashi, S., Fukami, T., Masuo, Y., Brocker, C.N., Xie, C., Krausz, K.W., et al. Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans. J. Lipid Res. jlr (2016), 2130–2137.
20. Zhang, Y., Klaassen, C.D., Effects of feeding bile acids and a bile acid sequestrant on hepatic bile acid composition in mice. J. Lipid Res. 51 (2010), 3230–3242.
21. Zhang, Y., Limaye, P.B., Lehman-McKeeman, L.D., Klaassen, C.D., Dysfunction of organic anion transporting polypeptide 1a1 alters intestinal bacteria and bile acid metabolism in mice. PLoS One, 7, 2012, e34522.
22. Wilson, K.H., Kennedy, M.J., Fekety, F.R., Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. J. Clin. Microbiol. 15 (1982), 443–446.
23. Heeg, D., Burns, D.A., Cartman, S.T., Minton, N.P., Spores of Clostridium difficile clinical isolates display a diverse germination response to bile salts. PLoS One, 7, 2012, e32381.
24. Theriot, C.M., Koenigsknecht, M.J., Carlson, P.E. Jr., Hatton, G.E., Nelson, A.M., Li, B., et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat. Commun., 5, 2014, 3114.
25. Buffie, C.G., Bucci, V., Stein, R.R., McKenney, P.T., Ling, L., Gobourne, A., et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517 (2015), 205–208.
26. Weingarden, A.R., Chen, C., Bobr, A., Yao, D., Lu, Y., Nelson, V.M., et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am. J. Physiol. Gastrointest. Liver Physiol., 306, 2014 G310–G9.
27. Winston, J.A., Theriot, C.M., Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract. Anaerobe, 2016, 44–50.
28. Sorg, J.A., Sonenshein, A.L., Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J. Bacteriol. 192 (2010), 4983–4990.
29. Francis, M.B., Allen, C.A., Sorg, J.A., Muricholic acids inhibit Clostridium difficile spore germination and growth. PLoS One, 8, 2013, e73653.
30. Carlson, P.E., Kaiser, A.M., McColm, S.A., Bauer, J.M., Young, V.B., Aronoff, D.M., et al. Variation in germination of Clostridium difficile clinical isolates correlates to disease severity. Anaerobe 33 (2015), 64–70.
31. Stabler, R.A., He, M., Dawson, L., Martin, M., Valiente, E., Corton, C., et al. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol., 10, 2009, R102.
32. He, M., Sebaihia, M., Lawley, T.D., Stabler, R.A., Dawson, L.F., Martin, M.J., et al. Evolutionary dynamics of Clostridium difficile over short and long time scales. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 7527–7532.
33. Sebaihia, M., Wren, B.W., Mullany, P., Fairweather, N.F., Minton, N., Stabler, R., et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat. Genet. 38 (2006), 779–786.
34. Perez, J., Springthorpe, V.S., Sattar, S.A., Clospore: a liquid medium for producing high titers of semi-purified spores of Clostridium difficile. J. AOAC Int. 94 (2011), 618–626.
35. Sprouffske, K., Wagner, A., Growthcurver: an R package for obtaining interpretable metrics from microbial growth curves. BMC Bioinform., 17, 2016, 1.
36. Winston, J.A., Thanissery, R., Montgomery, S.A., Theriot, C.M., Cefoperazone treated mouse model of Clostridium difficile strain R20291: a clinically relevant platform for testing therapeutics. J. Vis. Exp., 118, 2016, e56850.
37. Francis, M.B., Allen, C.A., Shrestha, R., Sorg, J.A., Bile acid recognition by the Clostridium difficile germinant receptor, CspC, is important for establishing infection. PLoS Pathog., 9, 2013, e1003356.
38. Sorg, J.A., Sonenshein, A.L., Bile salts and glycine as cogerminants for Clostridium difficile spores. J. Bacteriol. 190 (2008), 2505–2512.
39. Weingarden, A.R., Chen, C., Zhang, N., Graiziger, C.T., Dosa, P.I., Steer, C.J., et al. Ursodeoxycholic acid inhibits Clostridium difficile spore germination and vegetative growth, and prevents the recurrence of ileal pouchitis associated with the infection. J. Clin. Gastroenterol., 2015, 624–630.
40. Weingarden, A.R., Dosa, P.I., DeWinter, E., Steer, C.J., Shaughnessy, M.K., Johnson, J.R., et al. Changes in colonic bile acid composition following fecal microbiota transplantation are sufficient to control clostridium difficile germination and growth. PLoS One, 11, 2016, e0147210.
41. Kuehne, S.A., Cartman, S.T., Heap, J.T., Kelly, M.L., Cockayne, A., Minton, N.P., The role of toxin A and toxin B in Clostridium difficile infection. Nature 467 (2010), 711–713.
42. Darkoh, C., Brown, E.L., Kaplan, H.B., DuPont, H.L., Bile salt inhibition of host cell damage by Clostridium difficile toxins. PLoS One, 8, 2013, e79631.
43. Darkoh, C., DuPont, H.L., Norris, S.J., Kaplan, H.B., Toxin synthesis by Clostridium difficile is regulated through quorum signaling. MBio, 6, 2015 e02569–14.
44. Martin-Verstraete, I., Peltier, J., Dupuy, B., The regulatory networks that control Clostridium difficile toxin synthesis. Toxins, 8, 2016, 153.
45. Rudling, M., Understanding mouse bile acid formation: is it time to unwind why mice and rats make unique bile acids?. J. Lipid Res. 57 (2016), 2097–2098.